Sciety

TIRmed Pharma AB is a pharmaceutical company based in Bromma, Sweden, established in 2018. The company focuses on developing topical treatments for eczema, specifically targeting mild to moderate symptoms of atopic dermatitis. Its primary product is a non-steroidal cream designed to reduce inflammation and alleviate itching associated with the condition. TIRmed Pharma aims to address significant clinical needs within the dermatological space through its innovative drug candidates.

TIRmed Pharma AB is a pharmaceutical company based in Bromma, Sweden, established in 2018. The company focuses on developing topical treatments for eczema, specifically targeting mild to moderate symptoms of atopic dermatitis. Its primary product is a non-steroidal cream designed to reduce inflammation and alleviate itching associated with the condition. TIRmed Pharma aims to address significant clinical needs within the dermatological space through its innovative drug candidates.

Capitainer is a Swedish medical device company that develops volumetric blood collection devices for fixed-volume dried blood spots collected at home. The device enables patients to remotely collect a predefined blood volume, which can be mailed to a laboratory for analysis. The technology aims to reduce patient travel and healthcare resources required for blood sampling, while delivering improved accuracy over conventional methods and offering cost and environmental savings for healthcare providers handling large volumes of samples. Founded in 2016 and based in Stockholm, Capitainer focuses on enabling convenient, safe, and reliable remote blood collection for quantitative testing.

PharmNovo AB, established in 2008 and headquartered in Lund, Sweden, specializes in developing novel therapeutic drugs for neuro diseases, with a focus on reducing chronic pain through neuroscience and translational medicine. The company's primary product, PN6047, is designed to alleviate chronic pain and combat hypersensitivity disorders by targeting Delta Opioid Receptors (DORAs), distinct from traditional opioids that often lead to addiction and toxicity. PharmNovo aims to address the significant unmet medical need for safe and effective chronic pain treatments, affecting approximately 30% of adults in the United States and Europe.

Encare AB, established in 2009 and headquartered in Stockholm, Sweden, specializes in web-based software solutions designed to enhance post-surgical care. The company's primary product is an interactive platform supporting surgical clinics worldwide in implementing and maintaining Enhanced Recovery After Surgery (ERAS) protocols. This platform facilitates data collection, documentation, and follow-up on critical performance parameters, providing real-time feedback to improve efficiency and quality of care while generating substantial healthcare savings. Encare has rights to commercialize ERAS Society's surgical protocols and has rolled out its audit system to over 120 hospitals across 13 countries.

Capitainer is a Swedish medical device company that develops volumetric blood collection devices for fixed-volume dried blood spots collected at home. The device enables patients to remotely collect a predefined blood volume, which can be mailed to a laboratory for analysis. The technology aims to reduce patient travel and healthcare resources required for blood sampling, while delivering improved accuracy over conventional methods and offering cost and environmental savings for healthcare providers handling large volumes of samples. Founded in 2016 and based in Stockholm, Capitainer focuses on enabling convenient, safe, and reliable remote blood collection for quantitative testing.

Akiram Therapeutics is a Swedish biotech company based in Uppsala, specializing in the development of targeted radioimmunotherapy for cancer. The company's innovative approach utilizes a proprietary antibody that targets the cancer marker CD44v6, combined with a radiation component. This therapy has shown promising preclinical results in cancer models for conditions that currently lack effective treatments. Akiram's drug candidate is positioned to be classified as an orphan drug and has the potential to be recognized as first-in-class. The company is advancing research in various cancer indications, including head and neck cancer, acute myeloid leukemia, lung cancer, and aggressive thyroid cancer. With a team of experts in radiation science research, cancer precision medicine, and drug development, Akiram Therapeutics is dedicated to creating novel radioactive cancer-targeting molecules and pharmaceuticals aimed at improving diagnostics and therapeutic outcomes for patients with solid tumors.

PharmNovo AB, established in 2008 and headquartered in Lund, Sweden, specializes in developing novel therapeutic drugs for neuro diseases, with a focus on reducing chronic pain through neuroscience and translational medicine. The company's primary product, PN6047, is designed to alleviate chronic pain and combat hypersensitivity disorders by targeting Delta Opioid Receptors (DORAs), distinct from traditional opioids that often lead to addiction and toxicity. PharmNovo aims to address the significant unmet medical need for safe and effective chronic pain treatments, affecting approximately 30% of adults in the United States and Europe.

PharmNovo AB, established in 2008 and headquartered in Lund, Sweden, specializes in developing novel therapeutic drugs for neuro diseases, with a focus on reducing chronic pain through neuroscience and translational medicine. The company's primary product, PN6047, is designed to alleviate chronic pain and combat hypersensitivity disorders by targeting Delta Opioid Receptors (DORAs), distinct from traditional opioids that often lead to addiction and toxicity. PharmNovo aims to address the significant unmet medical need for safe and effective chronic pain treatments, affecting approximately 30% of adults in the United States and Europe.

Encare AB, established in 2009 and headquartered in Stockholm, Sweden, specializes in web-based software solutions designed to enhance post-surgical care. The company's primary product is an interactive platform supporting surgical clinics worldwide in implementing and maintaining Enhanced Recovery After Surgery (ERAS) protocols. This platform facilitates data collection, documentation, and follow-up on critical performance parameters, providing real-time feedback to improve efficiency and quality of care while generating substantial healthcare savings. Encare has rights to commercialize ERAS Society's surgical protocols and has rolled out its audit system to over 120 hospitals across 13 countries.

Capitainer is a Swedish medical device company that develops volumetric blood collection devices for fixed-volume dried blood spots collected at home. The device enables patients to remotely collect a predefined blood volume, which can be mailed to a laboratory for analysis. The technology aims to reduce patient travel and healthcare resources required for blood sampling, while delivering improved accuracy over conventional methods and offering cost and environmental savings for healthcare providers handling large volumes of samples. Founded in 2016 and based in Stockholm, Capitainer focuses on enabling convenient, safe, and reliable remote blood collection for quantitative testing.

Synartro is a Swedish research and development company specializing in the advancement of treatments for osteoarthritis (OA) through innovative drug delivery technology. The company focuses on developing local injection therapies that utilize patented delivery methods to combine existing proven drugs with enhanced efficacy, enabling sustained release without systemic side effects. Its lead program, SYN321, features a novel therapy that covalently binds diclofenac to hyaluronan, targeting knee osteoarthritis—a condition that affects many patients who currently experience inadequate pain relief. Synartro aims to improve the management of OA and has the potential to expand its offerings to include treatments for other related conditions in the future.

SAGA Diagnostics AB is a Swedish company specializing in personalized cancer diagnostics and disease monitoring through molecular genetic analyses, focusing on circulating tumor DNA (ctDNA). Founded in 2016 as a spin-out from a research group at Lund University, SAGA aims to enhance precision cancer medicine and improve patient survival rates with its minimally-invasive liquid biopsy testing services. The company provides a range of services, including gene mutation analysis and treatment monitoring, utilizing advanced technologies such as massively parallel sequencing. SAGA's proprietary tests enable oncologists and biopharmaceutical companies to detect actionable mutations, stratify patient groups, and monitor treatment responses with high sensitivity, thereby contributing significantly to advancements in cancer research and clinical diagnostics.

Capitainer is a Swedish medical device company that develops volumetric blood collection devices for fixed-volume dried blood spots collected at home. The device enables patients to remotely collect a predefined blood volume, which can be mailed to a laboratory for analysis. The technology aims to reduce patient travel and healthcare resources required for blood sampling, while delivering improved accuracy over conventional methods and offering cost and environmental savings for healthcare providers handling large volumes of samples. Founded in 2016 and based in Stockholm, Capitainer focuses on enabling convenient, safe, and reliable remote blood collection for quantitative testing.

Synartro is a Swedish research and development company specializing in the advancement of treatments for osteoarthritis (OA) through innovative drug delivery technology. The company focuses on developing local injection therapies that utilize patented delivery methods to combine existing proven drugs with enhanced efficacy, enabling sustained release without systemic side effects. Its lead program, SYN321, features a novel therapy that covalently binds diclofenac to hyaluronan, targeting knee osteoarthritis—a condition that affects many patients who currently experience inadequate pain relief. Synartro aims to improve the management of OA and has the potential to expand its offerings to include treatments for other related conditions in the future.

PharmNovo AB, established in 2008 and headquartered in Lund, Sweden, specializes in developing novel therapeutic drugs for neuro diseases, with a focus on reducing chronic pain through neuroscience and translational medicine. The company's primary product, PN6047, is designed to alleviate chronic pain and combat hypersensitivity disorders by targeting Delta Opioid Receptors (DORAs), distinct from traditional opioids that often lead to addiction and toxicity. PharmNovo aims to address the significant unmet medical need for safe and effective chronic pain treatments, affecting approximately 30% of adults in the United States and Europe.

Synartro is a Swedish research and development company specializing in the advancement of treatments for osteoarthritis (OA) through innovative drug delivery technology. The company focuses on developing local injection therapies that utilize patented delivery methods to combine existing proven drugs with enhanced efficacy, enabling sustained release without systemic side effects. Its lead program, SYN321, features a novel therapy that covalently binds diclofenac to hyaluronan, targeting knee osteoarthritis—a condition that affects many patients who currently experience inadequate pain relief. Synartro aims to improve the management of OA and has the potential to expand its offerings to include treatments for other related conditions in the future.

Elypta develops a liquid biopsy platform using metabolism-based biomarkers and artificial intelligence. Its platform measures glycosaminoglycan metabolites in blood and urine, aiming to enable earlier detection and monitoring of various cancer types.

Predicare designs and develops decision support systems for healthcare professionals. Its primary product, RETTS, aids in rapid patient assessment by measuring vital parameters and gathering medical history, enabling informed decisions in emergency care.

Athera Biotechnologies AB is a biopharmaceutical company based in Stockholm, Sweden, specializing in the development of targeted anti-inflammatory therapeutics and companion diagnostics for cardiovascular diseases (CVD). Founded in 2002, the company focuses on addressing unmet medical needs in the prevention and treatment of CVD through innovative approaches. Its product portfolio includes CVDefine, an immunological marker and ELISA kit designed for cardiovascular risk assessment, as well as several biopharmaceutical candidates. Among these is PC-mAb, a monoclonal antibody therapy aimed at preventing the uptake of oxidized low-density lipoprotein in macrophages, and Annexin A5, which seeks to prevent plaque rupture and atherothrombotic events. Athera's research is rooted in advancements made at the Karolinska Institutet and reflects a commitment to harnessing scientific breakthroughs for improved patient outcomes in the realm of cardiovascular health.

Founded in 2007, Likvor specializes in neurological investigation systems. Its flagship product, the CELDA System, assesses cerebrospinal fluid dynamics, enabling accurate diagnosis and monitoring of conditions like Normal Pressure Hydrocephalus (NPH) and shunt functionality.

Lipigon Pharmaceuticals AB is a Swedish biopharmaceutical company founded in 2010, specializing in the development of therapeutics for dyslipidemia and metabolic diseases. The company focuses on innovative treatments targeting lipoprotein lipase (LPL), an enzyme linked to fat metabolism, which plays a significant role in conditions such as insulin resistance and metabolic syndrome. Lipigon is particularly dedicated to addressing rare diseases, including lipodystrophy and homozygous familial hypercholesterolemia, where existing treatment options are limited. The company's expertise in fat metabolism has led to a collaborative agreement with AstraZeneca to develop LPL-based pharmaceuticals, potentially yielding up to $110 million in milestone payments based on development and sales achievements. Lipigon Pharmaceuticals is headquartered in Umeå, Sweden.

Cartana AB is a biotechnology company based in Solna, Sweden, established in 2017. The company specializes in mapping gene expression in brain tissue using In Situ Sequencing (ISS), a cutting-edge technology that allows for the simultaneous analysis of hundreds of genes within individual cells while preserving tissue morphology. Cartana's primary product, the NeuroKit: Brain Cell Mapping, can identify over 100 genes in a single tissue section, providing high sensitivity and throughput for various research applications. The company also offers sequencing services that include sample preparation in their laboratory. By enabling detailed analysis of brain cells and other tissues, Cartana supports advancements in research, biomarker discovery, treatment validation, and potential diagnostic tools. As of August 2020, Cartana operates as a subsidiary of 10x Genomics, Inc.

Medpro Clinic Group is a healthcare provider based in Sweden, operating six innovative care centers in the Västra Götaland region. The company offers a diverse range of medical services, including primary care, rehabilitation, vaccinations, dermatology, cardiology, and drug rehabilitation. Medpro Clinic Group is dedicated to delivering high-quality care with a personal touch, facilitated by a passionate and committed staff. By focusing on accessibility and continuity of care, the organization aims to meet the diverse healthcare needs of its patients effectively.

Liv Diagnostics, founded in 2016 and headquartered in Mölndal, Sweden, develops innovative diagnostic tools for cancer analysis. The company's primary product, CellRACE, measures the migration capacity of tumor cells to provide predictive information about the risk of metastasis. Unlike indirect diagnostic methods, Liv Diagnostics' technology directly analyzes cancer cell behavior by mimicking their natural environment in the human body. This approach allows physicians to observe how cells behave and treat them more efficiently.

Raytelligence AB is a Swedish company focused on developing advanced microwave sensors for the healthcare and industrial markets. Founded in 2015 as a subsidiary of Swedish Adrenaline, Raytelligence specializes in solutions that monitor vital signs such as heartbeat, movement, and body position. The company's flagship product, the RayVS1 sensor, is designed for home use and features capabilities for signal processing and analysis through a cloud service. In addition to its healthcare applications, Raytelligence has expanded into the industrial sector, securing clients in road construction and partnering with a major Swedish IT provider in the e-Health market. The team's expertise spans industrial design and radar signal processing, positioning Raytelligence as a key player in the development of innovative sensor technology.

MedFilm is a company focused on enhancing patient understanding of surgical interventions through the use of animated films. It specializes in creating three-dimensional animated patient films available in over a dozen languages, aimed at simplifying the communication of operations and treatments. These films are utilized in hospitals throughout Scandinavia, providing essential information to patients both upon admission and during recovery. Additionally, MedFilm's content is displayed on waiting room screens and made accessible online, ensuring that patients can easily access information about their procedures. By improving comprehension and encouraging patient participation, MedFilm supports healthcare providers in delivering better care.

Attana AB is a biotechnology company headquartered in Stockholm, Sweden, that specializes in providing biologically relevant information to enhance the efficiency of pharmaceutical drug development. Founded in 2002, the company develops advanced analytical biosensor instruments capable of automated analysis of molecular interactions with cells and tissues. Attana's third-generation biosensors are designed to assess binding characteristics such as specificity, kinetics, and affinity of various biomolecules, including cells, antibodies, proteins, viruses, and bacteria. The company's technology has been validated by academic institutions, biotech firms, and pharmaceutical companies globally. In addition to its biosensor products, Attana offers contract research services, catering to clients in Europe and Asia, including academic institutions and the pharmaceutical and biotechnology sectors.